Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
24 juin 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced partial adjournment of its 2022 Annual Meeting of...
Daré Bioscience to Participate in the 2022 BIO International Convention
06 juin 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
16 mai 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
12 mai 2022 06h00 HE
|
Daré Bioscience, Inc.
$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for...
Daré Bioscience Announces NIH Grant Award
11 mai 2022 08h00 HE
|
Daré Bioscience, Inc.
Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel...
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
05 mai 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience to Participate in Upcoming Conference
14 avr. 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
12 avr. 2022 08h00 HE
|
Daré Bioscience, Inc.
Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and...
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
31 mars 2022 08h00 HE
|
Daré Bioscience, Inc.
Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S....
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
24 mars 2022 08h00 HE
|
Daré Bioscience, Inc.
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...